Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Pancreatic Neoplasms 1Melanoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 19Paclitaxel 10Carboplatin 10Magnetic Resonance Spectroscopy 9Docetaxel 9Cyclophosphamide 9Specimen Handling 8Cisplatin 8Gemcitabine 7Drug Therapy 7sargramostim 6Pemetrexed 6Nivolumab 6fludarabine 5aldesleukin 5Trastuzumab 5Bevacizumab 5Taxes 4Fluorouracil 4Blood Specimen Collection 4Amifostine 4veliparib 3pegfilgrastim 3Topotecan 3Irinotecan 3IFL protocol 3Fluorodeoxyglucose F18 3Etoposide 3Early Intervention, Educational 3tariquidar 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × parsaclisib × Gynecologic × Clear all
NCT02646748 2022-03-31

Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

Incyte Corporation

Phase 1 Completed
159 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡